Medical Health & Life Science Research News

Lung Cancer Prognosis report explores the latest trends, forecast, opportunity growth analysis

Medical and Health

Lung Cancer Prognosis Market research report is a global study offering rich insights on market forecasts, latest market trends, market competition, and opportunity analysis.

Stratview Research announces the launch of a new research report on the Lung Cancer Prognosis Market by Epidemiology, By Treatment Algorithm in Different Regions, By Procedures (Thoracotomy (Lobectomy, Pneumonectomy, and Segmentectomy), Minimally Invasive), By Device (Surgical (Clamps, Forceps, Retractors, Others and by Monitoring Devices - Camera, Trocar and Endoscopic Instrument) and by Region (North America, Western Europe, Asia-Pacific, Latin America, Rest of the World)

This report, from Stratview Research, studies the global lung cancer prognosis over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

Lung Cancer Prognosis – The Global Lung Cancer Management Market in 2019

For the first time in market, one report exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters.

Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.

If we consider the Lung Cancer Management Market from the stakeholder’s perspective, then drugs approved for Small Cell Lung Cancer will not be applicable for Non-Small Cell Lung Cancer. What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away? Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors? Who all are the active players and who are newbies.

Will the differential cost of therapeutics across the regions impact the drug sales in North America versus APAC? In the Small Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow a CAGR of 7.44% globally however the same class of drugs might grow at a CAGR of 10.59% in the Non-Small Scale Lung Cancer Therapeutics Market in the same time period.

Click here to request the detailed TOC of the report:-

www.stratviewresearch.com/toc/425…arket.html

OR

Request a sample here:-

www.stratviewresearch.com/Request…arket.html

Considering that all the drugs mentioned above have a bright future till 2025, how many companies would like to compete in this market. How will the new joiners react if they consider that the market had a potential of USD 17.11 Billion alone in 2018 and is likely to grow at a CAGR of 8.28% globally till 2025.

In the Lung Cancer Diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision making process is equally high among the Lung Cancer Management Market.

The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.

Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.29%, over the course of forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%.

In some cases surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus – the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.31% over the course of seven years.

The study on the Lung Cancer Management Market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence it is the highly referred type of surgery procedure for NSCLC cases.

One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.

Among the different segments of Global Lung Cancer Management Market, connected health or Apps for Lung cancer maintenance or management are few. However, the segment is promising, as researchers believe that App based software can help in treatment adherence, keeping track of medical records (insurance companies, medical centres).

Developed markets such as USA, UK, Germany, France, Japan, China and Australia are the near term opportunities.

Lung cancer patients need nutritional supplements throughout their treatment phase followed by recovery and maintenance phase. The study from Stratview Research also looks at the aspects of sales and marketing, buying patterns of end users which can help companies such as Abbott, Danone, Nestle, B Braun and more gauge the market and look at the changing preferences of the market in regions such as Asia Pacific, Europe and North America.

Finally the report on Lung Cancer Prognosis also focuses on the regional aspects and gives the reader the flexibility to consider between global market as whole or regions in particular. It is imperative to look at this market as connected as out of the prevalent cases of Lung cancer are potential candidates of diagnosis and of the diagnosed pool a higher percentage will require medication or surgery, there will be few drop outs and few gaps, more or less all the above will need apps or Healthcare IT products to monitor drug adherence, doctor access, and above all long term nutritional supplement.

Hence, readers may consider this inter-linked market under the Lung cancer management market and consider the opportunities that exist in each segment from 2019-2025.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value.

It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

  • Market structure: Overview, industry life cycle analysis, supply chain analysis
  • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
  • Market trend and forecast analysis
  • Market segment trend and forecast
  • Competitive landscape and dynamics: Market share, Product portfolio, New product launches, etc.
  • Attractive market segments and associated growth opportunities
  • Emerging trends
  • Strategic growth opportunities for the existing and new players
  • Key success factors
  • Future outlook

The Burning Questions This Report Will Answer:

  1. Over 1.5 million people worldwide die from lung cancer per year; why does the disease still has an extremely poor prognosis with all the modern technology?
  2. What are the options available for accurate prediction of lung cancer?
  3. Which market is more lucrative pharma, diagnostics or surgery?
  4. Which technologies are available currently and how will the future technologies disrupt the market?

The Global Lung Cancer Prognosis Market is segmented into the following categories:

By Treatment Algorithm

  • APAC
  • North America
  • Western Europe
  • Rest of The World

By Demand & Supply

  • Import
  • Export

By Device

  • Surgical (Clamps, Forceps, Retractors, Others)
  • Monitoring Devices (Camera, Trocar and Endoscopic Instrument)

By End-User

  • Decision Maker
  • Decision Making Process

By Region

  • North America (Country Analysis: the USA, Canada)
  • Western Europe (Country Analysis: Germany, France, the UK)
  • Asia-Pacific (Country Analysis: China, Japan, India, and Rest of Asia-Pacific)
  • Latin America (Country Analysis: Brazil, Argentina, Mexico, and Others)
  • Rest of the World (Sub-Region Analysis: The Middle East, Africa, Rest of Europe and Others)

Stratview Research has several high value market reports in the healthcare & life science industry. Please refer to the following link to browse through our reports:

www.stratviewresearch.com/market-…ences.html

News From

Stratview Research - Market ResearcherStratview Research
Category: Market Research Publishers and RetailersCompany about: Stratview Research is a global market intelligence and strategic research firm offering wide range of services including syndicated market reports, custom research, and procurement intelligence across industries such as Advanced Materials, Composites, Aerospace and Defense, Automotive and Transportation, Construction and Equipment, Energy and Utility, Consumer Goods, Marine, and Oil and Gas.
This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Make an Inquiry about this report HERE!
  • www.stratviewresearch.com
  • www.stratviewresearch.com/425/lun…arket.html
  • www.stratviewresearch.com/toc/425…arket.html
  • www.stratviewresearch.com/Request…arket.html
  • www.stratviewresearch.com/contact
  • www.stratviewresearch.com/market-…ences.html